(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids...
Stats | |
---|---|
Šios dienos apimtis | 16 959.00 |
Vidutinė apimtis | 11 282.00 |
Rinkos kapitalizacija | 14.49M |
EPS | $0 ( 2024-04-03 ) |
Kita pelno data | ( $-0.120 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.540 |
ATR14 | $0.0510 (0.44%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-21 | Barbier Ann | Buy | 40 000 | Stock Option (right to buy) |
2023-06-21 | Geraghty James A | Buy | 45 000 | Stock Option (right to buy) |
2023-06-21 | Kiener Peter A | Buy | 40 000 | Stock Option (right to buy) |
2023-06-21 | Kiritsy Christopher P | Buy | 40 000 | Stock Option (right to buy) |
2023-06-21 | Richman Michael | Buy | 40 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
17.10 |
Last 97 transactions |
Buy: 6 636 987 | Sell: 4 508 050 |
Tūris Koreliacija
Pieris Pharmaceuticals Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Pieris Pharmaceuticals Koreliacija - Valiuta/Žaliavos
Pieris Pharmaceuticals Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $42.81M |
Bruto pelnas: | $41.03M (95.84 %) |
EPS: | $-21.80 |
FY | 2023 |
Pajamos: | $42.81M |
Bruto pelnas: | $41.03M (95.84 %) |
EPS: | $-21.80 |
FY | 2022 |
Pajamos: | $25.90M |
Bruto pelnas: | $23.12M (89.27 %) |
EPS: | $-0.420 |
FY | 2021 |
Pajamos: | $31.42M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.675 |
Financial Reports:
No articles found.
Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.